Clinical Trial Update: Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating carfilzomib with dexamethasone in multiple myeloma patients who previously underwent a stem cell transplant was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Kyprolis (carfilzomib)

Snippet

Sponsor: Mayo Clinic | Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 2 | Status: WITHDRAWN